- Agriculture
- Antibiotic/anti-viral
- Biologics
- Biomarkers
-
By Clinical Application
- Anesthesiology
- Blood & Lymphatic Disease
- CNS & Neurosciences
- Dermatology
- Diabetes, Metabolism, Endocrinology & Obesity
- Ear, Nose, & Throat
- Gastroenterology & Digestive Disease
- General & Plastic Surgery
- Health Education, Medical Training and Operations
- Heart and Vascular
- Immunology, Autoimmune & Inflammation
- Infectious Diseases
- Mental Health
- Multiple clinical applications
- Musculoskeletal Disorders, Orthopedics/Bone
- Nephrology/Renal
- Oncology
- Ophthalmology
- Orphan Diseases
- Pediatrics
- Physical Medicine & Rehabilitation
- Radiology
- Regenerative Medicine / Tissue Engineering
- Reproductive Health: Obstetrics & Gynecology
- Respiratory & Pulmonary
- Surgery
- Transplantation
- Urology
- Wound Healing
- COVID-19
- Creative Works
- Diagnostics
- Drug Delivery
- Drug screening and discovery
- Energy, Cleantech & Environmental
- Engineering & Physical Sciences
- Gene therapy
- Imaging
- Materials
- Medical Devices
- Nutraceuticals
- Other
- Research & Design Tools
- RNAi/siRNA
- Sensors & Controls
- Small molecules
- Software & Information Technology
- Stem Cells
- Vaccines
Showing 5 matches for the following: Inventor: "Lyerly, Herbert" ×
Revolutionary inhibitor target for enhanced immune response against breast cancer relapse
Unmet Need In the US, it is estimated that 1 in 8 women will develop breast cancer, of which 78% are estrogen receptor-positive (ER+) cases. These ER+ breast cancers are known for their risk of…
Chemical modulators of immune checkpoints and cell growth for cancer treatment
Unmet Need Each year there are over 1.6 million new cases of cancer in the US, and over 600,000 cases prove fatal. Treating various types of cancer can be particularly challenging because of the complex…
CD47/SIRPα checkpoint blockade in combination with HER2 antibody for the treatment of HER2-positive breast cancer
Value Proposition Approximately 20% of breast cancers overexpress the human epidermal growth factor receptor type 2 (HER2), which is recognized as an oncogenic driver of an aggressive cancer phenotype with a poor prognosis. The clinical…
Chemical modulators of immune checkpoints and therapeutic use
Compounds and pharmaceutical compositions that down-regulate immune checkpoints such as PD-1, PD-L1 and CTLA-4 are provided. Also provided are methods of treating a disease by down-regulating immune checkpoints such as PD-1, PD-L1 and CTLA-4. The…
Novel mutation-resistant smoothened inhibitors for cancer therapy
Value Proposition The hedgehog signaling pathway is an important mediator of developmental and cellular differentiation processes in both embryonic and adult tissues, but can also promote tumor growth and progression if dysregulated. Two forms of…